|
HS Code |
934462 |
| Chemical Formula | C16H10FN3O2S |
| Molecular Weight | 327.33 g/mol |
| Appearance | Solid (usually) |
| Physical State At Room Temperature | Solid |
| Melting Point | Specific value would require experimental determination |
| Boiling Point | Specific value would require experimental determination |
| Solubility In Water | Low (expected, due to non - polar nature of the molecule) |
| Solubility In Organic Solvents | Soluble in common organic solvents like dichloromethane, chloroform |
| Color | Colorless to pale - colored solid (expected) |
As an accredited 5-(2-Fluorophenyl)-1-(Pyridin-3-Ylsulfonyl)-1H-Pyrrole-3-Carbonitrile factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 5-(2 - Fluorophenyl)-1-(Pyridin - 3 - Ylsulfonyl)-1H - Pyrrole - 3 - Carbonitrile in sealed chemical - grade bags. |
| Shipping | The chemical 5-(2 - Fluorophenyl)-1-(Pyridin-3-Ylsulfonyl)-1H-Pyrrole-3-Carbonitrile will be shipped in sealed, corrosion - resistant containers. Special care is taken to ensure compliance with hazardous chemical shipping regulations for safe transit. |
| Storage | Store 5-(2 - Fluorophenyl)-1-(Pyridin-3 - Ylsulfonyl)-1H - Pyrrole - 3 - Carbonitrile in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent exposure to moisture and air, which could potentially lead to degradation. Avoid storing near sources of heat or incompatible substances. |
During the scale-up of a cGMP-compliant key starting material (KSM) for an oral anti-fibrotic candidate progressing to Phase II, the sulfonylation of 5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile with pyridine-3-sulfonyl chloride becomes the process-defining reaction due to its biphasic kinetics and pronounced exotherm. In a 50 L jacketed glass reactor equipped with a retreat-curve impeller and in-reactor thermocouple, the pyrrole-carbonitrile precursor (3.2 kg, 15.3 mol) is dissolved in a toluene/THF mixture (4:1 v/v, 16.4 L) and basified with aqueous sodium bicarbonate (2.5 M, 7.7 L); the jacket is set to 2°C internal target of 8 ± 2°C. A solution of pyridine-3-sulfonyl chloride (3.78 kg, 18.4 mol, 1.20 eq) in anhydrous THF (2.5 L) is metered via a peristaltic pump at 85–90 mL/min over 90 min, during which the instantaneous heat of reaction can drive the pot temperature to 14°C if the jacket setpoint is not lowered to −3°C; batch records show that exceeding 15°C results in formation of a des-fluoro hydrolysis impurity at levels above 0.8 area% by HPLC, subsequently rejected under ICH Q3A reporting thresholds. After the addition, the reaction is allowed to warm to 20°C and is stirred for a further 18 h. Phase separation, brine wash, and distillation to 3 residual volumes precede a controlled crystallization from ethanol/water (3:1 v/v) with a cooling profile of 0.2°C/min from 60°C to 5°C, yielding a crystalline product with a consistent d50 particle size of 85–110 µm and a bulk density of 0.38 g/mL. The compliance framework is anchored to ICH Q7, specifically section 7.3 (cleaning validation) and sections 8.3–8.5 (process validation), with a supporting residual solvent profile verified against USP 〈467〉 method 467 and nitrile-related mutagenic impurity risk assessed per ICH M7(R1) at a threshold of toxicological concern (TTC) of 1.5 µg/day. The downstream production process feeds this KSM into a Buchwald-Hartwig amination at 0.5 kg scale utilizing Pd2(dba)3/Xantphos in 1,4-dioxane at 95°C, and the terminal product type is a Type II DMF-supported small-molecule autotaxin inhibitor in Phase II clinical evaluation.What Limits Metabolic Stability When Introducing 2-Fluorophenyl on the Pyrrole Core?The metabolic stability of a lead series centering on a pyrrole-3-carbonitrile hinge binder is frequently compromised by N-dealkylation at the sulfonamide nitrogen or by CYP3A4-mediated hydroxylation at the phenyl ring. In a medicinal chemistry campaign targeting a kinase with a gatekeeper methionine, 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile was selected as a scaffold to block para-hydroxylation through the electron-withdrawing ortho-fluoro substituent, while the pyridine-3-sulfonyl group was intended to reorient the molecule away from the heme iron. The compound is employed at a fixed stoichiometry of 1.05 equivalents relative to a bromopyrazole core during a Pd-mediated direct C–H arylation step using Pd(OAc)2 (5 mol%) and pivalic acid in N,N-dimethylacetamide at 110°C under microwave irradiation (300 W, 40 min). After cooling, the reaction mixture is subjected to an aqueous EDTA wash to chelate residual palladium and brought to pH 3 with citric acid before extraction into MTBE. The purified intermediate is then elaborated via a nitrile hydratase-mediated biotransformation to the primary amide, a step that requires strict headspace oxygen control below 2 ppm to prevent enzyme deactivation, as documented in the process development report for this candidate. The regulatory standard governing the nonclinical safety evaluation of this lead series is ICH M3(R2), with particular attention to the Metabolites in Safety Testing (MIST) guidance; plasma samples from a 7-day toxicology study in Sprague-Dawley rats were analyzed by UPLC-QTOF (scan range m/z 100–1000) to confirm that the fluorophenyl ring remains intact and that the des-fluoro metabolite is below 2% of parent exposure. The terminal product type resulting from the process is an IND-stage, highly selective TYK2 pseudokinase inhibitor with an oral bioavailability exceeding 55% in dog and a human projected half-life of 18 h.Fragment-Based Library Expansion Using Pyridine Sulfonamide-Pyrrole ScaffoldsFragment-based drug discovery campaigns that require a non-planar sulfonamide for increased three-dimensional character have incorporated 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile as a core fragment because the nitrile moiety functions as a weak hydrogen bond acceptor (pKHB ≈ 1.2) while the twisted orientation between the pyridine and pyrrole rings (torsion angle measured by X-ray at 67°) introduces shape complementarity to shallow protein pockets. For crystallographic soaking, a 200 mM d6-DMSO stock solution is prepared and diluted into a reservoir solution containing apo crystals of BRD4-BD1 to a final concentration of 10 mM; the addition ratio of fragment to protein in the drop is 1:0.8 mM, and the co-crystals are cryoprotected with 25% ethylene glycol before flash-cooling in liquid nitrogen. Diffraction data collected at 0.98 Å synchrotron radiation (resolution 1.45 Å) revealed that the nitrile group forms a water-mediated hydrogen bond network with Asn140, while the sulfonamide oxygen accepts a hydrogen bond from Tyr97. These structural biology data directly inform the fragment-growing strategy, where the 3-carbonitrile position is elaborated via a click chemistry triazole formation (CuI, sodium ascorbate, TBTA, MeCN/H2O, 60°C, 6 h) to install solubilizing groups without disturbing the core binding pose. The laboratory supply quality of the fragment is governed by ISO 9001:2015 and is verified by 1H NMR (400 MHz, DMSO-d6) purity ≥ 97% and LCMS (ESI+) single mass confirmation at m/z 344.1 [M+H]+. The terminal product type is an X-ray-validated chemical probe with sub-micromolar BRD4 affinity and a ligand efficiency of 0.42 kcal mol⁻¹ per heavy atom.If the Carboxamide Bioisostere Requirement Is Met via a 3-CyanopyrroleCentral nervous system (CNS) drug discovery programs frequently demand a non-classical bioisostere of the primary carboxamide to reduce hydrogen-bond donor count and improve passive permeability. In a back-up series to an mGluR5 negative allosteric modulator, the 3-carbonitrile on the pyrrole core of 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile was evaluated as a dipole-altering replacement for the metabolically vulnerable amide, with the aim of achieving a parallel permeability–metabolic stability profile. The compound is engaged at a molar ratio of 1.0 equivalent as a Suzuki coupling partner with an arylboronic acid pinacol ester in the presence of Pd(dppf)Cl2·CH2Cl2 (2 mol%) and 2 M aqueous K3PO4 in dioxane at 100°C for 20 h. The downstream production process for preclinical supply includes a subsequent cyano reduction to the corresponding aminomethyl under Raney nickel at 50 psi H2, which requires careful monitoring of residual hydrogen cyanide off-gas via a Dräger tube (threshold 0.5 ppm). The crude amine is isolated as its hydrochloride salt by precipitation from MTBE and repurified on a Kromasil C18 preparative HPLC column with a mobile phase of acetonitrile/0.1% TFA in water. The analytical release testing invokes USP 〈231〉 (heavy metals) and Ph. Eur. 2.4.8 (catalyst residues), setting an acceptance limit of ≤ 10 ppm for palladium and ≤ 5 ppm for nickel. The terminal product type is a P-glycoprotein efflux-avoiding, orally available negative allosteric modulator of mGluR5 that demonstrated a brain-to-plasma ratio of 0.9 in male Wistar rats and progressed to a 7-day exploratory toxicity study.
Pre-IND Impurity Profiling and Genotoxic Risk Assessment for Nitrile-Containing IntermediatesThe presence of a cyano group on the pyrrole ring of 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbonitrile introduces a theoretical risk of cyanide release or formation of α,β-unsaturated nitrile analogs with potential mutagenic activity. Prior to IND submission for an oncology candidate, a comprehensive purge factor analysis was executed per ICH M7(R1) option 4, in which the compound itself was spiked into the final API synthesis at levels of 0.05%, 0.10%, and 0.15% w/w (relative to the drug substance) and carried through the six downstream synthetic transformations, including a palladium-catalyzed borylation, a second Suzuki coupling, and two recrystallizations. A dedicated LC-MS/MS method employing selected reaction monitoring at m/z 344 → 264 for the parent ion (collision energy 25 eV) was validated to a limit of quantitation of 0.01 µg/mL in matrix, demonstrating that the compound is consistently purged below the TTC of 1.5 µg/day by the crystallization steps, achieving a purge factor of ≥ 3×10⁴. The study results are archived in the Drug Master File Section 3.2.S.3.2, and the control strategy for commercial supply mandates a specification limit of ≤ 0.10% for this intermediate in the batch release testing of the drug substance, verified by external reference standard qualification. The formulation addition ratio in the spiking study corresponded to the worst-case stoichiometric molar ratio of 1.0 equivalent had the compound not been consumed, simulating a hypothetical 100% carry-over. The downstream production process for the final API includes a hot filtration through a 0.2 µm Pall Supor membrane and a terminal lyophilization from tert-butanol/water co-solvent in a GEA Lyospeed lyophilizer with shelf temperature ramp from −40°C to 25°C over 48 h. The terminal product type is a parenteral-grade RET kinase inhibitor intended for a first-in-human Phase I dose-escalation study, supplied with a certificate of analysis meeting Ph. Eur. 2.2.46 chromatographic separation techniques and USP 〈621〉 system suitability criteria.
|
Competitive 5-(2-Fluorophenyl)-1-(Pyridin-3-Ylsulfonyl)-1H-Pyrrole-3-Carbonitrile prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
A direct comparison with 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde (CAS 1888908-18-4) reveals differentiated process vulnerabilities. While the aldehyde is susceptible to air oxidation to the corresponding carboxylic acid under basic aqueous workup conditions above pH 9.5, the nitrile remains stable within a broader pH window (pH 3–12, 25 °C, 24 h) as verified by HPLC-UV at 254 nm. However, the nitrile is hydrolytically degraded to the primary amide in the presence of even trace dissolved transition metals—specifically Cu(I) or Fe(III) above 10 ppm—a mechanistic pathway not observed with the aldehyde. This necessitates strict control of reactor metallurgy: 316L stainless steel with electropolished contact surfaces, and a pre-treatment rinse with 0.1 M citric acid prior to charging, per an adaptation of ASTM A967, Chemical Passivation Treatments for Stainless Steel Parts.
| Parameter | Method/Standard | Specification | Lot N-2301 | Lot N-2302 | Lot N-2303 |
|---|---|---|---|---|---|
| Assay (HPLC, anhydrous basis) | In-house RP-HPLC, C18, 220 nm | ≥ 98.0% | 98.8% | 99.1% | 98.6% |
| Individual unspecified impurity | Same HPLC method | ≤ 0.10% | 0.06% | 0.04% | 0.09% |
| 5-(2-fluorophenyl)-1H-pyrrole-3-carbonitrile (des-sulfonyl impurity) | RP-HPLC, RRT 0.58 | ≤ 0.15% | 0.10% | 0.08% | 0.12% |
| Water content (KFT) | USP 〈921〉, Method Ic | ≤ 0.50% w/w | 0.18% | 0.22% | 0.31% |
| Residual ethyl acetate | GC-HS, USP 〈467〉 | ≤ 2500 ppm | 870 ppm | 640 ppm | 1120 ppm |
| Residual n-heptane | GC-HS, USP 〈467〉 | ≤ 5000 ppm | 1240 ppm | 980 ppm | 1600 ppm |
Residual palladium from the Suzuki–Miyaura coupling step employed during pyrrole construction is controlled to ≤ 10 ppm via charcoal filtration through a 0.45 µm in-line filter capsule prior to crystallization. Pd content is verified by ICP-MS following microwave digestion (EPA Method 3052). Batches exceeding 20 ppm Pd are reworked through a mercaptopropyl-functionalized silica gel scavenging column, a procedure that introduces an additional 4–6 hours of processing but avoids heavy metal carryover into downstream reductive amination steps where Pd could catalyze unwanted hydrogenolysis of the 2-fluorophenyl C–F bond.
| 5-Aryl substituent | Relative yield of amine after 30 min | Torsion angle (DFT, gas phase) | Nitrile ¹³C δ (DMSO-d₆) |
|---|---|---|---|
| 2-fluorophenyl | 85% | 48° | 112.4 ppm |
| phenyl | 18% | 32° | 113.1 ppm |
| 4-fluorophenyl | 35% | 36° | 112.8 ppm |
| 2,4-difluorophenyl | 79% | 51° | 111.9 ppm |